Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Updated: 1st of every month (unless a weekend)

Clear filter
663 clinical trials found
Clinical trials

NBI-1065845-MDD3027

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder [MDD] (NCT07196501)

A prospective, multi-centre, single-arm non-randomised phase 2 clinical trial. This study will aim to deliver SABR to the prostate 35 Gy in 5 fractions, one fraction per week, in individuals with de novo metastatic prostate cancer.
Currently recruiting

NBI-1065845-MDD3028

A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder [MDD] (NCT06966401)

This trial is direct entry only for anyone who completed the 3027 program
Coming soon

NeoFOL-R

Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter Randomized, controlled trial (NeoFOL-R) (ACTRN12624000005550)

Currently recruiting

NIMBLE

Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype (NCT04718389)

No longer recruiting

NIMBLE-AZD0466

A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies (NCT04865419)

Currently recruiting

NIVO-LD

Safety, immunogenicity and efficacy of low dose Nivolumab in adults living with HIV on antiretroviral therapy (ART): NIVO-LD (NCT05187429)

Currently recruiting

NKX019-103 Ntrust-2

A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer [CAR NK] Cell Therapy, in Subjects with Immune-Mediated Diseases (NCT06733935)

The Ntrust-2 study is looking for adults ages 18–70 to take part in research on an investigational cell therapy, called NKX019. NKX019 is being studied to see if it can safely target the root cause of systemic sclerosis (SSc or scleroderma), idiopathic inflammatory myopathy (IIM or myositis) or ANCA-associated vasculitis (AAV or polyangiitis). NKX019 is made from natural killer (NK) cells, which are white blood cells and a normal part of everyone’s immune system. For this study, NK cells are collected from healthy donors and specially processed into NKX019. NKX019 is made from white blood cells called natural killer (NK) cells. NK cells are the immune system’s first responders and possess a unique, natural ability to target and kill disease-causing cells. NK cells are a normal part of the immune system and are present in everyone. The NK cells used in NKX019 are collected from healthy donors and then processed for use in NK cell therapy.
Currently recruiting

NVG-2089-201

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy [CIDP]

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to potentially help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.
Currently recruiting

Ocean-Lpa

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein[a] (NCT05581303)

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

Currently recruiting

OCEANIC AF

A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke (NCT05643573)

No longer recruiting

OCEANIC-STROKE

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA (NCT05686070)

Currently recruiting

Odyssey Study

A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerative Colitis (NCT06850727)

The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC). In addition, the study will evaluate the potential of OD-07656 to enhance the therapeutic benefit of vedolizumab when given after OD-07656.
Currently recruiting

Olympia-1

A Phase 3, open-label, randomized study to compare the efficacy and safety of Odronextamab [REGN1979], an Anti-CD20 X Anti-CD3 bispecific antibody, versus investigators choice in previously untreated participants with Follicular Lymphoma. (NCT06091254)

Currently recruiting

OPTIMA

Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (ISRCTN42400492)

No longer recruiting

ORCHID

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID). (NCT04157335)

No longer recruiting

ORIGIN-1

ORganoId GuIded N-of-1 (ORIGIN-1) trial (ACTRN12623001136695)

Currently recruiting

PACE AUGMENT-AF

PACEmaker AUGMENTed AF ablation in participants with AF and sinus node disease – the PACE AUGMENT-AF Study (ACTRN12625000546459)

This study evaluates whether increased atrial pacing rate decreases AF recurrence and burden for patients with AF and sinus node dysfunction undergoing AF ablation.
Currently recruiting

PACIFICA

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/µL) (NCT03165734)

Currently recruiting

PC_ASP_006

A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (NCT05238116)

Currently recruiting

PEPSTEP

Perampanel for the prevention of post-stroke epilepsy: a pilot phase II randomised controlled trial (ACTRN12618001984280)

Currently recruiting
21 22 23 24 25